TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection

This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately controlled severe asthma. A total of 660 subjects are expected to be enrolled, with subjects randomized in a 1:1 ratio to receive either TQC2731 (420 mg Q4W) or placebo (Q4W) via subcutaneous (SC) administration.

NCT Number	NCT06829784
Lead Sponsor	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions	Asthma
Enrollment	660 participants
Start Date	2025-03-21
Primary Completion	2027-12 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-06-17